001     825201
005     20210129225236.0
024 7 _ |a 10.1088/1742-6596/746/1/012069
|2 doi
024 7 _ |a 1742-6588
|2 ISSN
024 7 _ |a 1742-6596
|2 ISSN
024 7 _ |a 2128/13409
|2 Handle
024 7 _ |a WOS:000409470900069
|2 WOS
037 _ _ |a FZJ-2016-07672
082 _ _ |a 530
100 1 _ |a Nawroth, T.
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Target Nanoparticles for Therapy - SANS and DLS of Drug Carrier Liposomes and Polymer Nanoparticles
260 _ _ |a Bristol
|c 2016
|b IOP Publ.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1484058771_19267
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a T arget Nano-Pharmaceutics shall improve therapy and diagnosis of severe diseases, e.g. cancer, by individual targeting of drug-loaded nano-pharmaceuticals towards cancer cells, and drug uptake receptors in other diseases. Specific ligands, proteins or cofactors, which are recognized by the diseased cells or cells of food and drug uptake, are bound to the nanoparticle surface, and thus capable of directing the drug carriers. The strategy has two branches: a) for parenteral cancer medicine a ligand set (2-5 different, surface-linked) are selected according to the biopsy analysis of the patient tissue e.g. from tumor.; b) in the oral drug delivery part the drug transport is enforced by excipients/ detergents in combination with targeting materials for cellular receptors resulting in an induced drug uptake. Both targeting nanomaterials are characterized by a combination of SANS + DLS and SAXS or ASAXS in a feedback process during development by synthesis, nanoparticle assembly and formulation.
536 _ _ |0 G:(DE-HGF)POF3-6G15
|f POF III
|x 0
|c POF3-6G15
|a 6G15 - FRM II / MLZ (POF3-6G15)
536 _ _ |a 6G4 - Jülich Centre for Neutron Research (JCNS) (POF3-623)
|0 G:(DE-HGF)POF3-6G4
|c POF3-623
|f POF III
|x 1
588 _ _ |a Dataset connected to CrossRef
650 2 7 |a Medicine
|0 V:(DE-MLZ)SciArea-190
|2 V:(DE-HGF)
|x 0
650 1 7 |a Health and Life
|0 V:(DE-MLZ)GC-130-2016
|2 V:(DE-HGF)
|x 0
693 _ _ |a Forschungs-Neutronenquelle Heinz Maier-Leibnitz
|e KWS-2: Small angle scattering diffractometer
|f NL3ao
|1 EXP:(DE-MLZ)FRMII-20140101
|0 EXP:(DE-MLZ)KWS2-20140101
|5 EXP:(DE-MLZ)KWS2-20140101
|6 EXP:(DE-MLZ)NL3ao-20140101
|x 0
700 1 _ |a Johnson, R.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Krebs, L.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Khoshakhlagh, P.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Langguth, P.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Hellmann, N.
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Goerigk, G.
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Boesecke, P.
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Bravin, A.
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Duc, G Le
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Szekely, N.
|0 P:(DE-Juel1)145431
|b 10
|u fzj
700 1 _ |a Schweins, R.
|0 P:(DE-HGF)0
|b 11
773 _ _ |a 10.1088/1742-6596/746/1/012069
|g Vol. 746, p. 012069 -
|0 PERI:(DE-600)2166409-2
|n 1
|p 012069 -
|t Journal of physics / Conference Series
|v 746
|y 2016
|x 1742-6596
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/825201/files/Nawroth_2016_J._Phys.__Conf._Ser._746_012069.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/825201/files/Nawroth_2016_J._Phys.__Conf._Ser._746_012069.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:825201
|p openaire
|p VDB:MLZ
|p driver
|p open_access
|p VDB
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 10
|6 P:(DE-Juel1)145431
913 1 _ |a DE-HGF
|9 G:(DE-HGF)POF3-6G15
|x 0
|4 G:(DE-HGF)POF
|v FRM II / MLZ
|1 G:(DE-HGF)POF3-6G0
|0 G:(DE-HGF)POF3-6G15
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-600
|b Forschungsbereich Materie
|l Großgeräte: Materie
913 1 _ |a DE-HGF
|b Forschungsbereich Materie
|l Von Materie zu Materialien und Leben
|1 G:(DE-HGF)POF3-620
|0 G:(DE-HGF)POF3-623
|2 G:(DE-HGF)POF3-600
|v Facility topic: Neutrons for Research on Condensed Matter
|9 G:(DE-HGF)POF3-6G4
|x 1
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2016
915 _ _ |a Creative Commons Attribution CC BY 3.0
|0 LIC:(DE-HGF)CCBY3
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)JCNS-FRM-II-20110218
|k JCNS (München) ; Jülich Centre for Neutron Science JCNS (München) ; JCNS-FRM-II
|l JCNS-FRM-II
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)JCNS-FRM-II-20110218
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21